Sanofi: Q4 sales growth of 10.3%, 2024 business EPS guidance exceeded, and strong business EPS rebound expected in 2025 Paris, January 30, 2025 Q4: sales growth of 10.3% at CER1 and business EPS2 of €1.31 Pharma launches up 56.5%, reaching sales of €0.8 …

The Akron Press Club's Wednesday public health panel coincided with the United States Senate confirmation hearing for Robert F. Kennedy Jr., President Donald Trump’s pick for health secretary. It’s also been five years since COVID-19 entered the U.S. …

As neurology continues to evolve, the first half of 2025 is set to be a crucial period, with key clinical trial results expected to shape the field. These trials, covering a wide range of neurological disorders, have the potential to deepen our …

CLEVELAND, Ohio (WOIO) -Mono has long-plagued teenagers and young adults, with terrible fatigue and sore throats for weeks, without treatment or cure. A Northeast Ohio doctor’s office is working on a new vaccine that seeks to eradicate mono and the virus …

ModeX Therapeutics Inc., an OPKO Health company, announces dosing of the first participant in the phase I study (NCT06655324) of an Epstein-Barr virus (EBV) vaccine candidate being developed in collaboration with Merck, known as MSD outside the United …

Epstein-Barr virus (EBV) causes infectious mononucleosis and is associated with several types of cancer and multiple sclerosis There are no current treatments or vaccines for EBV First participant dosed with novel investigational EBV vaccine targeting …

The following is a summary of “Self-reported longitudinal COVID-19 vaccination reactogenicity profiles in persons with multiple sclerosis,” published in the December 2024 issue of Neurology by Briggs et al.   Preventing severe COVID-19 outcomes remains …

Paris: Sanofi has announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to tolebrutinib for the treatment of adults with non-relapsing secondary progressive multiple sclerosis (nrSPMS). This is based on …

Tolebrutinib designated Breakthrough Therapy by the FDA for non-relapsing secondary progressive multiple sclerosis Designation is based on positive results from the HERCULES study in adults with non-relapsing secondary progressive multiple sclerosis ( …

… CD20 in multiple sclerosis: pharmacology, efficacy … Vaccine-breakthrough SARS-CoV-2 infections in people with multiple sclerosis … with relapsing multiple sclerosis treated with … multiple sclerosis. Vaccines. 2023;11(5):978. doi:10.3390/vaccines11050978 …